Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).

NCT02546661 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02546661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02546661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 28, 2016
Completion date
November 30, 2026
Enrollment
117 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder cancer